SOMAí Pharmaceuticals August 2023 Newsletter
Our August was filled with activity as we prepared for the launch of our products in the EU and Australia this September.
We are proud to announce that SOMAí has received authorisation for our facility located in Lisbon, Portugal, from the Portuguese Health Authority INFARMED) . This authorisation permits SOMAí to manufacture, import, and export medicinal cannabis products to numerous global markets and represents a significant step for us towards revenue generation. SOMAí Pharmaceuticals also announces that we have successfully raised €5 million of new capital to fund our ambitious growth plans.?
This INFARMED authorisation awards SOMAí a GMP Certificate Part I and Part II, enabling us to execute our plan to own distribution channels in Australia and Germany and to establish distribution partnerships in another eight countries whilst developing a comprehensive brand of medical cannabis products. SOMAí’s goal is to be a singular brand that services all doctors' and patients' needs through multiple delivery systems and novel formulations.
Learn more about our products in the Product Catalogue.
We've completed phase two of our expansion, adding clean room production space and new product lines, including soft gel capsules, sublingual and transdermal tablets, vape cartridges, and syringe filling. Not only do we have the most complete offering in the pharmaceutical cannabis space, but we are already working on next-generation products that will be equally impressive as our initial launch.We are pleased to announce the opening of our new office in Australia, which marks our global expansion. Sonya Breen will be leading our team in Australia as the Country Director. She will ensure that our distributors, doctors, and patients receive efficient communication and assistance.
Apart from that, our company is currently in the process of obtaining our distribution license in Germany. We are confident in our efforts and are anticipating the expansion of our representation in Poland, Italy, and the UK this year. ?At SOMAí, we are committed to fostering new partnerships in other regions as we continue to progress with our go-to-market strategy.
Throughout August, Michael Sassano had a business tour across Australia, Cape Town, Johannesburg in South Africa, and Lesotho. During this journey, alongside the Australian team, he has attended the Australian Medicinal Cannabis Symposium in Brisbane. Keep an eye out for his article on his travels. It was more than cannabis; it was a real eye-opening experience.
领英推荐
SOMAí?- September highlights:?
In September, we will start our soft launch, registering products in many countries, and plan for a full hard launch by early 2024. Already, our APIs have exciting traction as a precursor to our full catalogue offering. We will be showcasing our new robust flower catalogue this September to complement our formulations. Stay tuned.
We are excited to announce that SOMAí Pharmaceuticals will participate in Expopharm in Düsseldorf, Germany, and Medical Cannabis Europe in Lisbon, Portugal. If you would like to schedule a meeting with our team to discuss potential collaborations with SOMAí Pharmaceuticals, please don't hesitate to contact us at [email protected] .
Check our latest useful links
You can get information about SOMAí products and services in the Product Catalogue
We are also thrilled to announce that we have done?extensive research on SOMAí Pharmaceuticals. You can read the complete research here:?SOMAí Equity Research
Latest articles from our CEO, Michael Sassano
Currently team is running 50 acres outdoor for extraction, 100k sq feet of indoor, and 300k sq feet of green house with supplemental lighting. Also building 20k sq feet ethanol/ butane manufacturing. NYC/NJ/MD
1 年GMP is a requisite to operate correct?